SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Autres langues Shin Nippon Biomedical Laboratories, Ltd.

Actions

2395

JP3379950003

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 02/05/2024			Varia. 5j.	Varia. 1 janv.
1 535 ^JPY	-0,45 %		+6,01 %	-9,60 %

02/02	Shin Nippon Biomedical Laboratories, Ltd. communique ses prévisions de résultats consolidés pour l'exercice se terminant le 31 mars 2024	CI
2023	Shin Nippon Biomedical Laboratories, Ltd. annonce le versement d'un dividende intérimaire pour l'année 2024, payable le 30 novembre 2023 ; donne des indications sur le dividende pour l'année 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02/02
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	18/01
Shin Nippon Biomedical Laboratories : 英語版株主通信（2023/04/01~2023/09/30）を発行しました	27/12
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	07/11
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	02/08/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02/08/23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	16/06/23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	15/06/23
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15/06/23
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	08/06/23
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	08/05/23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08/05/23
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18/04/23
Sector Update: Health Care Stocks Higher Premarket Monday	17/04/23
Bank Earnings in Focus as US Equity Futures Tread Water	17/04/23
Top Premarket Gainers	17/04/23
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	17/04/23
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	17/04/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Shin Nippon Biomedical Laboratories, Ltd.

Actions

2395

JP3379950003

Autres langues

Filtres